

[Translation: Please note that the following purports to be a translation from the Japanese original Notice of Resolution of the 110th Annual General Meeting of Shareholders for the business term ended December 31, 2020 of Chugai Pharmaceutical Co., Ltd. prepared for the convenience of shareholders outside Japan with voting rights. However, in the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Securities Code: 4519)

March 23, 2021

To the Shareholders:

**NOTICE OF RESOLUTION OF
THE 110th ANNUAL GENERAL MEETING OF SHAREHOLDERS**

We are pleased to announce that the matters below were reported and resolved at the 110th Annual General Meeting of Shareholders of Chugai Pharmaceutical Co., Ltd. held today (the "AGM").

Yours very truly,

Osamu Okuda
Representative Director, President
CHUGAI PHARMACEUTICAL CO., LTD.
(the "Company")
1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku,
Tokyo

PARTICULARS

Matters Reported:

The Business Report for the Business Term (January 1, 2020 to December 31, 2020, the "Term"), Non-Consolidated Financial Statements for the Term, Consolidated Financial Statements for the Term, and the Report on the Results of Audit of the Consolidated Financial Statements by the Accounting Auditor and Audit & Supervisory Board

The contents of the above were reported.

Matters Resolved:

First Proposal

Appropriation of Surplus

This item was approved and resolved as originally proposed. Appropriation of surplus for the end of the Term was decided to be JPY30 per share of common stock of the Company, and JPY49,316,132,430 in an aggregate amount.

Second Proposal

Election of Five (5) Directors

This item was approved and resolved as originally proposed. Five (5) Directors, namely, Masayuki Oku, Yoichiro Ichimaru, Christoph Franz, William N. Anderson and James H. Sabry were reelected and assumed office.

Directors Masayuki Oku and Yoichiro Ichimaru satisfy the condition of Outside Director, respectively.

Third Proposal

Election of One (1) Audit & Supervisory Board Member

This item was approved and resolved as originally proposed. One (1) Audit & Supervisory Board Member, namely, Yoshiaki Ohashi was newly elected and assumed office.

– End –

Directors and Audit & Supervisory Board Members

Based on the resolution by the Board of Directors and the Audit & Supervisory Board which were held after the AGM, Directors and Audit & Supervisory Board Members of the Company are as follows:

Representative Director, Chairman	Tatsuro Kosaka		Director	William N. Anderson	reelected
Representative Director, Deputy Chairman	Motoo Ueno		Director	James H. Sabry	reelected
Representative Director, President	Osamu Okuda		Full-time Audit & Supervisory Board Member	Atsushi Sato	
Outside Director	Masayuki Oku	reelected	Full-time Audit & Supervisory Board Member	Yoshiaki Ohashi	newly elected
Outside Director	Yoichiro Ichimaru	reelected	Outside Audit & Supervisory Board Member	Takaaki Nimura	
Outside Director	Mariko Y Momoi		Outside Audit & Supervisory Board Member	Yuko Maeda	
Director	Christoph Franz	reelected	Outside Audit & Supervisory Board Member	Kenichi Masuda	

New management structure of the Company, as of April 1, 2021, will be as follows:

Deputy President	Shinya Unno	Vice President	Hiroyuki Matsumoto
Executive Vice President	Hisafumi Okabe	Vice President	Yoshiyuki Yano
Executive Vice President	Toshiaki Itagaki	Vice President	Satoko Shisai
Executive Vice President	Tetsuya Yamaguchi	Vice President	Junichi Nezu
Senior Vice President	Junichi Ebihara	Vice President	Tsukasa Kusano
Senior Vice President	Mark Noguchi	Vice President	Kaori Ouchi
Vice President	Minoru Watanabe	Vice President	Shinya Takuma
Vice President	Shinji Hidaka		